Coeur to Participate in the RBC Capital Markets Global Mining & Materials Conference
The RBC Capital Markets Global Mining & Materials Conference is an invitation-only investment conference. Presentation materials will be made available on the Company's website at www.coeur.com.
About Coeur
Coeur Mining, Inc. is a U.S.-based, well-diversified, growing precious metals producer with five wholly-owned operations: the Las Chispas silver-gold mine in Sonora, Mexico, the Palmarejo gold-silver complex in Chihuahua, Mexico, the Rochester silver-gold mine in Nevada, the Kensington gold mine in Alaska and the Wharf gold mine in South Dakota. In addition, the Company wholly-owns the Silvertip polymetallic critical minerals exploration project in British Columbia.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
2 hours ago
- CBC
Built by coal: Sask. community fights to keep burning fuel in face of an uncertain future
The rolling Prairie hills around Estevan reveal deep layers of black rock, a vast deposit of coal that has been mined in this part of Saskatchewan for more than 100 years. The natural resource that powers the local economy, keeps the lights on and is a central part of the local identity was expected to be left in the ground going forward, with the anticipated shutdown of two nearby power plants within the next five years. Mayor Tony Sernick, who grew up near a coal mine on the outskirts of the city, said the outlook for a future without coal was initially bleak. "It's our livelihood, it's in our DNA," he said. "There was no optimism on the horizon. Everybody was kind of planning for the worst." But the worst case appears to have been avoided, at least for now. The Saskatchewan government recently announced plans to extend the life of its coal-fire power plants for decades, arguing Ottawa doesn't have jurisdiction over electricity generation in the province. Fear of losing a third of the population Estevan sits just north of the U.S. border, about 185 kilometres southeast of Regina. Known as the Energy City because of the coal, oil and gas industries, Estevan was once projected to lose a third of its population of about 11,000 people. About 400 homes went up for sale as the economy contracted and some residents began to leave. Like many small coal towns across Canada, the community was bracing for the phase out of coal-fired power plants. A looming federal deadline, with commitment by the province, set a target of eliminating the polluting fossil fuel by 2030. Some feared Estevan could become a "ghost town." The community worked to find ways to diversify its economy and was selected by the Saskatchewan government as the site of a small modular nuclear reactor. But Sernick said an extension of coal was still needed and is welcome news. "It was good to see you kind of filled that gap, and it really gives us that time to transition into whatever the next big thing is," he said. The business community is also looking for ways to adapt. Merissa Scarlett, executive director of the Estevan Chamber of Commerce, said the news the plants would keep running came as a "relief." "Even with coal being back in, we're still going to move to nuclear. The world's changing, right?," she said. "We have to diversify the economy." The city has received millions of dollars from the federal and provincial governments to help support a transition away from coal to new economic opportunities. One of those ideas: a research project underway to see if the area's coal can be turned into graphite. 'I think we're safe' Outside Estevan's grocery store, residents are clear: they don't want coal to go without an alternative for the economy. Lynn Senchuk said she believes coal will keep burning, even if the federal government tries to wind down operations. "I think we're safe," she said. Derrick Helm said he supports bringing in a nuclear power plant, but believes coal should keep going until it's no longer needed. "It's nonstop in the ground. Just keep pulling it out and burning it," he said. "I have no problem with that." The fight over coal The local push to keep burning coal, along with continued support from the province, could leave Estevan as one of the last places in Canada to use the fossil fuel. In 2016, Ottawa gave provinces until 2030 to phase out coal-fired power plants. Those fitted with carbon capture technology receive an exemption, including one unit at the Boundary Dam 3 station outside Estevan. But Saskatchewan recently announced plans to run all three of its plants well beyond the deadline, arguing that the federal government lacks jurisdiction over power generation. The decision is already facing a legal challenge in court. Brett Dolter, an economist and expert on climate change policy at the University of Regina, said it's unclear how much the province might need to invest in refurbishing the plants and keeping them running. "There was a plan, and now we have this possibility of wasting a lot of money to switch horses midstream to go with reinvesting in what is an outdated technology," he said. "We know that burning coal is the dirtiest way to produce power. We have many, many other options and it really is short-sighted to think that's the best option for Saskatchewan." Saskatchewan has Canada's second-most emissions-intensive electricity system, trailing only Alberta. Despite being only three percent of the country's population, it's responsible for about a quarter of all electricity emissions, according to the federal government. Alberta's last coal plant powered down last year. "We're only three per cent of the population, but we're the last holdouts to phase out coal," Dolter said. "So we're this dirty island of electricity." A spokesperson for the federal Minister of Environment and Climate Change said Saskatchewan has an agreement with Ottawa on emission reduction measures. It's set to expire at the end of next year. If the terms are not respected, "it can be terminated, thus bringing the federal regulations back into full effect," Keean Nembhard wrote in an email. Premier Scott Moe said the province wants to see the federal rules change. "We're going to be operating those plans into the future to provide affordable, reliable power for Saskatchewan residents and Saskatchewan industries, as we transition to a much cleaner nuclear power source," he said at a recent news conference. Relief for now On Fourth Street, Estevan's main drag, residents and business owners are breathing a sigh of relief for now. The 400 homes for sale has dropped to 50, and hundreds of workers are expected to arrive in the city to help refurbish the power plants and eventually build the nuclear facility. "Things are looking up," said Lori Smith, outside her downtown embroidery shop. "It's scary when they were talking about closing and how many people were going to leave town. But I know that there's a lot of power behind the energy sector in Estevan." Lynda Chamney's fiancé works at one of the plants.
Globe and Mail
3 hours ago
- Globe and Mail
Could Buying PayPal Stock Today Set You Up for Life?
Key Points PayPal's stock underperformed the S&P 500 over the past decade. It struggled with the loss of eBay, macro headwinds, and competitive challenges. Its stock looks cheap, but it probably won't deliver life-changing gains. 10 stocks we like better than PayPal › PayPal (NASDAQ: PYPL), one of the world's largest digital payment platforms, was spun off from eBay 10 years ago. If you had invested $1,000 in PayPal's stock on that first day's opening trade, your investment would have grown to $7,411 when it closed at its all-time high in July 2021. But at its current price of $70, that investment would have shrunk back down to about $1,680. That $1,000 invested in an S&P 500 index fund would have grown to around $3,220 during the same period. Let's see why PayPal's stock underperformed the market and if it might eventually deliver life-changing gains. What happened to PayPal over the past few years? In 2018, eBay announced it would replace PayPal with Adyen, its smaller Dutch competitor, as its preferred payment platform over the following five years. That loss was shocking, but PayPal's rapid growth during the pandemic -- which was driven by surging online orders and peer-to-peer payments -- temporarily offset that pressure. During an investor day in early 2021, then-CEO Dan Schulman boldly claimed that from 2020 to 2025, the company could nearly double its number of year-end active accounts from 377 million to 750 million, more than double its annual revenue to over $50 billion, and more than double its annual free cash flow (FCF) from $5 billion to over $10 billion. But as the pandemic passed, its growth in active accounts, total payment volume (TPV), and revenue slowed down. Data source: PayPal. That's why it was surprising when Schulman abandoned those ambitious targets in 2022 and vacated the CEO position in late 2023. At the end of 2024, PayPal had only 434 million active accounts. For the full year, it generated only $31.8 billion in revenue with FCF of $6.6 billion. That slowdown was caused by inflationary headwinds for consumer spending, competition from other digital payment platforms, and its gradual loss of eBay's revenue. Its take rate, or the percentage of each transaction it retains as revenue, has also dropped every year since its split from eBay. That decline was exacerbated by its growing dependence on its peer-to-peer payments app Venmo and back-end software platform Braintree -- which both have lower take rates than its main platform -- for its TPV and revenue growth. However, PayPal still expanded its core platform with more buy now, pay later (BNPL) services, cryptocurrency trading tools, and deeper partnerships with credit card companies like Visa and Mastercard. It also launched more services to deepen its penetration of brick-and-mortar stores, more perks for its cards, and its own PayPal USD (CRYPTO: PYUSD) stablecoin for cross-border transfers and high-yield savings accounts. As PayPal expanded, it streamlined its spending to boost its operating margins, which rose from 15.3% in 2020 to 16.7% in 2024 on the basis of generally accepted accounting principles (GAAP). Its earnings per share under GAAP grew at a steady compound annual rate of 3% during those four years. What will happen to PayPal over the next few years? The current CEO, Alex Chriss, is trying to balance that expansion with more disciplined spending. He also plans to plow a lot of its FCF into big buybacks to boost earnings per share (EPS). The company's near-term growth should be driven by new tools like PayPal Open, which bundles its payments, financial services, and risk management tools in a unified platform; PayPal World, which is cross-compatible with other popular overseas payment platforms; Pay With Venmo, which is integrated into more physical and online stores, and its streamlined Fastlane checkout service. The expanded use of its own stablecoins and fresh AI features could also lock in more users. From 2024 to 2027, analysts expect PayPal's revenue and EPS to have a compound annual growth rate of 6% and 16%, respectively. So while its high-growth days might be over, its tighter spending and buybacks should drive its EPS higher. Based on those expectations, its stock looks cheap at just 14 times this year's earnings. Is PayPal a stock that will set you up for life? PayPal survived its loss of eBay, continues to gain new accounts, and is trading at low valuations. It's still a reliable long-term play on the secular expansion of the digital payments market, but its business is maturing and probably won't set you up for life on its own. Should you invest $1,000 in PayPal right now? Before you buy stock in PayPal, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and PayPal wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
20 hours ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
